



(51) International Patent Classification:

A61K 47/10 (2006.01) A61K 47/38 (2006.01)
A61K 9/06 (2006.01) A61K 8/73 (2006.01)
A61K 47/36 (2006.01) A61K 8/86 (2006.01)

(21) International Application Number:

PCT/EP2015/061282

(22) International Filing Date:

21 May 2015 (21.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14169457.0 22 May 2014 (22.05.2014) EP

(71) Applicant: UNIVERSITY OF COPENHAGEN
[DK/DK]; Nørregade 10, DK-1165 Copenhagen (DK).

(72) Inventors: BAR-SHALOM, Daniel; Rypevænget 213,
DK-2980 Kokkedal (DK). JACOBSEN, Jette; Lupinvej
23, DK-3650 Ølstykke (DK). DALBY, Kasper; Filo-
sofgangen 23, 1, DK-5000 Odense C (DK). PEDERSEN,
Anne Marie Lyng; Skjoldgårdsvej 6, DK-2920 Charlott-
tenlund (DK). VILMANN, Peter; Klampenborgvej 19,
DK-2930 Klampenborg (DK).

(74) Agents: KLINGE, Ulla et al.; Inspicos A/S, P.O. Box 45,
Kogle Allé 2, DK-2970 Hørsholm (DK).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: AQUEOUS GEL COMPOSITION AND ITS USE

(57) Abstract: An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.



WO 2015/177288 A1

AQUEOUS GEL COMPOSITION AND ITS USE

FIELD OF THE INVENTION

The present invention relates to an aqueous gel as well as its use. More particularly the present invention relates to an aqueous gel showing transparency, lubricity, stringiness, elongation, extensiveness and cohesiveness while being devoid of taste and smell and not being tacky. The aqueous gel according to the invention may be used as a lubricant, e.g. as carrier for active ingredients such as local anaesthetics, analgesics and other API's and as a carrier for excipients, as a saliva replacement or food lubricant, and as a lubricant on mucosal surfaces, serosal surfaces and skin. Other uses may be submucosal application either for endoscopic mucosal lifting or for carrier of excipients.

BACKGROUND OF THE INVENTION

Hydrophilic polymers are well known in the art as rheology modifiers of aqueous systems. For instance, they are used as thickeners for a wide range of functional systems such as cosmetics, personal care products and medicine.

Local anaesthetics for use in the throat of a patient undergoing direct oro-pharyngeal examination or surgery or endoscopic examination of the upper gastrointestinal tract or respiratory tract are known in the dosage forms of sprays or viscous gels. However, the known products have a number of drawbacks. Thus, those products are mostly disliked by patients as they have an offending taste and numb, besides the intended site, the tongue and parts of the buccal cavity. A spray, while usually applied with a long nozzle directly to the throat, is transported as aerosol by the breathing to the oral cavity. A gel, usually applied with a spoon may spill on the way or regurgitate into the mouth. In the case of endoscopy procedures, the gel may interfere with the clarity of the images.

Artificial saliva or saliva substitutes can be used to replace moisture and lubricate in the oral cavity and thereby alleviate oral dryness. These substitutes are available commercially, but they can also be compounded. Artificial salivas are formulated to mimic natural saliva. However, they are often proven to be ineffective for most patients suffering from persistent salivary gland hypofunction and xerostomia (i.e., sensation of dry mouth).

Saliva is important for the maintenance of oral health, and also plays an essential role in a number of oral and gastrointestinal functions. Consequently, patients with reduced salivary secretion and changes in their saliva composition are more susceptible to dental caries, oral infections and

mucosal lesions, and often have symptoms of a dry and sore mouth, burning and itching oral mucosa, difficulties in chewing and swallowing dry foods, impaired sense of taste, difficulty in speaking, and problems with acid reflux. These distressing consequences of salivary hypofunction also have a significant negative impact on quality of life and general health status. Several
5 diseases and medical conditions as well as the medications used for treating them, are associated with salivary gland hypofunction (objective evidence of diminished salivary output) and xerostomia (subjective sensation of dry mouth). In autoimmune diseases like Sjögren's syndrome, salivary gland dysfunction is largely related to structural changes in the salivary glands.

10 Patients who have undergone radiotherapy to cancer in the head and neck region also often have reduced or no saliva production due to destruction of the gland tissue.

Patients with salivary gland hypofunction often add sauces and gravy to foods in large amounts to compensate for the lack of saliva but in the case of salads and fruits which do not readily form a bolus, this does not help, taste becomes a problem and taking artificial saliva can be awkward and embarrassing (as well as ineffective). Further, by changing the taste of
15 the food item, sauces and gravies make it harder to fully appreciate the original taste. These problems with eating can lead to weight loss, nutritional insufficiency, social isolation and impaired quality of life.

Commercially available products come in a variety of formulations including solutions, sprays, gels and lozenges. In general, they contain an agent to increase viscosity, such as
20 carboxymethylcellulose or hydroxyethylcellulose, minerals such as calcium and phosphate ions and fluoride, preservatives such as methyl- or propylparaben, flavourings and related agents. Attempts have been made to include "natural components" of saliva such as hyaluronic acid or mucins but the results have been disappointing and those products are expensive.

25 Different spray formulations are available, which are meant to be applied directly to the mouth and throat of a patient suffering from salivary gland hypofunction before swallowing a food item. Alternatively (or alongside), the patient liquefies the food in a blender or food processor.

30 The use of these formulations is associated with social stigmatization, as it will be obvious for everyone that the patient is struggling with the intake of food.

US 4,740,365 discloses a sustained-release preparation used for mucous membranes in the oral cavity.

US 5,068,225 relates to a viscoelastic fluid for use in surgery and other therapies and method of using same.

US 6,133,325 relates to bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions.

- 5 US 8,823,334 relates to a topical anesthetic containing about 3 wt% to 10 wt% tetracaine in a vehicle suitable for administration to the mucosa.

WO 92/03124 discloses a polymeric complex composition comprising a reaction complex formed from a polycarbophil and alginic acid.

WO 92/09256 relates to a water-based human tissue lubricant.

- 10 WO 02/087519 relates to shaving compositions containing highly lubricious water soluble polymers.

US 2005/0226822 relates to oral care products containing ovomucin.

- 15 US2005/0244521 discloses a tobacco composition comprising tobacco and a "format", wherein said composition is readily disintegrable in the mouth, and wherein said format may comprise a polymer.

WO 2006/028578 discloses use of polyethylene glycol based fluidized polymer suspension in functional systems.

- 20 WO 2006/124219 discloses a shaving composition comprising water, a water dispersible surface active agent, a lubricious water soluble polymer, water insoluble particles, and a hydrogel-forming polymer.

EP 0 613 684 relates to a solid form product for alleviating xerostomia.

There is, however, a need for a lubricant for mucosal membranes, serosal surfaces and for submucosal applications in the form of a gel which exhibits stringiness and lubricity while not being tacky.

OBJECT OF THE INVENTION

It is an object of embodiments of the invention to provide an aqueous gel composition which acts as a lubricant for mucosal membranes, serosal surfaces or skin, and which exhibits stringiness, lubricity and is non-tacky.

- 5 It is a further object of embodiments of the invention to provide a gel composition which fills as many functions of the natural saliva as possible; it lubricates the mouth enabling normal speech, provides a comfortable feeling of hydration, wetting and lubrication, blends efficiently with solid food and lubricates the passage of food through the throat.

- 10 It is a further object of embodiments of the invention to provide a gel, which acts as a carrier for active ingredients to the oral cavity and throat such as local anaesthetics, analgesics, anti-inflammatory agents, anti-infective agents such as antifungal, antibacterial, antiviral and anti-parasitic agents, carries preventive agents, and optionally, pH regulating agents, flavouring agents, taste correcting substances, texture modifiers, colourants and preservatives.

- 15 It is a further object of embodiments of the invention to provide a gel which is used to lubricate insertion of devices and appliances to other body cavities such as vagina, uterus, rectum, urethra, ear canal, lacrimal duct, nose, sinuses, thoracic and abdominal cavity and oesophagus.

- 20 It is a further object of embodiments of the invention to provide an aqueous gel composition which may be used to lift the mucosa by submucosal injection either in order to perform endoscopic submucosal resection/dissection or to function as a carrier of active substances.

SUMMARY OF THE INVENTION

- 25 It has been found by the present inventors that, by combining at least one polysaccharide and at least one high molecular weight polyethylene oxide in a composition having a high water content, an aqueous gel composition having a desirable combination of properties is obtained.

So, in a first aspect the present invention relates to an aqueous gel composition comprising:

- a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition; and

b) a local anaesthetic agent or an analgesic agent;

for use as a local anaesthetic or analgesic.

In a second aspect the present invention relates to an aqueous gel composition comprising:

- a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition; and
- b) optionally a caries-preventive agent, an antifungal agent, an antibacterial agent, an antiviral agent, an anti-parasitic agent, a flavouring agent, a taste correcting substance, a texture modifier, a colourant, a pH regulating agent, and a preservative;

10 for use as a saliva substitute.

In a third aspect the present invention relates to an aqueous gel composition comprising:

- a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition; and
- 15 b) optionally a caries-preventive agent, an antifungal agent, an antibacterial agent, an antiviral agent, an anti-parasitic agent, a flavouring agent, a taste correcting substance, a texture modifier, a colourant, a pH regulating agent, and a preservative;

for use as a food lubricant.

In a fourth aspect the present invention relates to an aqueous gel composition comprising

20 water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is above 98 % by weight of the composition, more preferably in the range 98.5-99.5 % by weight of the composition, such as in the range 98.7-99.3 % by weight of the composition.

In a fifth aspect the present invention relates to an aqueous gel composition according to the

25 invention for use as a lubricant for mucosal membranes, serosal surfaces, skin and for submucosal applications.

In a sixth aspect the present invention relates to an aqueous gel composition according to the invention for use as a lubricant for devices and appliances.

DETAILED DISCLOSURE OF THE INVENTION

Definitions

The term "aqueous gel" refers to an aqueous dispersion comprising water and a hydrophilic polymeric substance dispersed therein.

- 5 The term "additive" refers to any active ingredient for use in an aqueous gel composition according to the invention. Non-limiting examples thereof include local anaesthetics, analgesics, anti-inflammatory agents, anti-infective agents such as antifungal, antibacterial, antiviral and anti-parasitic drugs, anti-caries agents or caries-preventive agents, and excipients such as pH regulating agents, preservatives, texture modifiers, colourants,
10 flavouring agents and taste correcting substances.

The term "polysaccharide" refers to a polymeric carbohydrate molecule composed of long chains of monosaccharide units bound together by glycosidic linkages.

- The term "cellulose" refers to an organic compound with the general formula $(C_6H_{10}O_5)_n$, a polysaccharide consisting of a linear chain of several hundred to over ten thousand $\beta(1\rightarrow4)$
15 linked D-glucose units. A "derivative" of cellulose refers to a cellulose compound, wherein the hydroxyl groups thereof are partially or fully reacted with various substituents.

- The terms "polyethylene oxide" (PEO) and polyoxyethylene (POE) refer to a polyether compound of the general formula $H-(O-CH_2-CH_2)_n-OH$. Polyethylene glycol (PEG) has the same structure as PEO/POE but the starting monomers ethylene oxide and ethylene glycol
20 respectively and the synthesis methods used are different.

The term "saliva substitute" refers to a substance used to substitute the saliva in patients having a dry mouth or xerostomia.

The term "food lubricant" refers to a preparation which, when added to food prior to insertion into the mouth will, upon mastication enable the formation of an easily swallowable bolus.

- 25 The terms "lubricancy" and "lubricity", which in the present context are used interchangeably, refers to the property of a composition to lubricate, i.e. make slippery, smooth and lessen friction.

Specific embodiments of the invention

In an embodiment of the invention the water content of the aqueous gel composition is at least 95 % by weight of the composition, more preferably at least 97 % by weight of the composition. Thereby a gel having highly desirable properties in terms of stringiness, lubricity and cohesiveness may be obtained.

In an embodiment of the invention the water content is above 98 % by weight of the composition, more preferably in the range 98.5-99.5 % by weight of the composition, such as in the range 98.7-99.3 % by weight of the composition.

In an embodiment of the invention the at least one polysaccharide is selected from the group consisting of cellulose and derivatives thereof, optionally substituted alkylcelluloses, gums, pectin, carrageenan and alginates.

In an embodiment of the invention the at least one cellulose and derivatives thereof, optionally substituted alkylcelluloses, gums, pectin and carrageenan is selected from the group consisting of methylcellulose, carboxy-methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, tara gum, guar gum, arabic (Acacia) gum, gellan gum, pullulan gum, cassia gum, carob gum, carageenan, pectin, locust bean gum, welan gum, konjac, and karaya.

In an embodiment of the invention the methylcellulose, carboxy-methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, tara gum, guar gum, arabic (Acacia) gum, gellan gum, pullulan gum, cassia gum, carob gum, carageenan, pectin, locust bean gum, welan gum, konjac, and karaya is preferably selected from the group consisting of methylcellulose, carboxy-methylcellulose, hydroxypropylmethylcellulose, xanthan gum, and guar gum, more preferably methylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, gellan gum or xanthan gum. The above polysaccharides are devoid of any taste and smell and are available at low cost.

In an embodiment of the invention the at least one polysaccharide is a methylcellulose or a hydroxypropylmethyl cellulose and is preferably hydroxypropylmethyl cellulose (HPMC). Methylcellulose and hydroxypropyl methylcellulose are available commercially under the trade name METHOCEL™ as a line of cellulose ether products produced by The Dow Chemical Company. The initial letter identifies the type of cellulose ether. An "A" identifies methylcellulose products and "E", "F", "K", "J" and "310-series" identify different hydroxypropyl methylcelluloses.

In an embodiment of the invention the at least one high molecular weight polyethylene oxide is of a molecular weight of at least 200,000, preferably of a molecular weight of at least 600,000, preferably of a molecular weight of at least 1,000,000, such as in the range 1,000,000 to 7,000,000, more preferably of a molecular weight in the range 1,000,000-6,000,000, such as of a molecular weight in the range 1,000,000 to 5,000,000, such as of a molecular weight in the range 1,000,000 to 4,000,000. Polyethylene oxide polymers are available commercially under the trade name of POLYOX™ followed by a subscript indicating its type. Thus e.g. POLYOX™ 301 refers to a PEO having a molecular weight of approximately 4,000,000, whereas POLYOX™ 303 refers to a PEO having a molecular weight of approximately 7,000,000.

In an embodiment of the invention the content of the at least one polysaccharide is in the range 0.1-3 % by weight of the composition, more preferably in the range 0.3-2.0 % by weight of the composition, such as in the range 0.4-1.5 % by weight of the composition, more preferably in the range 0.5-1.5 % by weight of the composition, such as about 0.6-1.2 % by weight of the composition, such as about 0.8 % by weight of the composition.

In an embodiment of the invention the content of the at least one high molecular weight polyethylene oxide is in the range 0.05-2 % by weight of the composition, more preferably in the range 0.1-1 % by weight of the composition, more preferably in the range 0.1-0.5 % by weight of the composition, such as about 0.3 % by weight of the composition.

In an embodiment of the invention the content of the at least one polysaccharide in the composition is in the range 0.5-1.5 % by weight of the composition, preferably in the range 0.6-1.2 % by weight of the composition, such as about 0.8 % by weight of the composition, and the content of the at least one high molecular weight polyethylene oxide in the composition is in the range 0.1-1 % by weight of the composition, preferably in the range 0.1-0.5 % by weight of the composition, such as about 0.3 % by weight of the composition.

In an embodiment of the invention the aqueous gel composition according to the invention comprises a local anaesthetic agent or analgesic agent selected from procaine, amethocaine, cocaine, lidocaine (also known as Lignocaine), prilocaine, bupivacaine, levobupivacaine, ropivacaine, mepivacaine, dibucaine, benzocaine, tetracaine, etidocine, and ropivacaine. It is to be understood, however, that the above list is non-exhaustive and that other local anaesthetic agents or analgesic agents may be used in a particular aqueous gel composition according to the invention.

In an embodiment of the invention the aqueous gel composition further comprises at least one additive. Non-limiting examples thereof include additives selected from the group

consisting of a flavouring agent, a taste correcting substance, a texture modifier (such as one or more lipids), a colourant, a pH regulating agent, a preservative, a therapeutically active agent, such as sucralfate, a steroid, a caries-preventive agent (such as e.g. fluoride), an antifungal agent, an antibacterial agent (such as e.g. Lysozyme, triclosan, metronidazole),
5 an antiviral agent (acyclovir), and an anti-parasitic agent. A person skilled in the art will readily be able to select any suitable additive according to the purpose intended and it is to be understood, that the above list is non-exhaustive and merely illustrate exemplary additives and that other additives may be used singly or in combination in a particular aqueous gel composition according to the invention.

- 10 The aqueous gel composition according to the invention may be prepared in a manner known per se. Thus, non-limiting examples of the preparation thereof may be found in Handbook of Pharmaceutical Excipients, fifth ed., Raymond C Rowe et al. and include mixing of the polymers with ice-cold water under vigorous agitation; wetting the polymers with a portion of hot, 65-85°C, water and then adding, under agitation, the rest of the water as ice or ice-
15 water; or the polymers may be moistened with an organic solvent such as ethanol prior to the addition of water.

In an embodiment of the invention the aqueous gel composition comprises an active ingredient for the treatment of oral mucosal conditions/diseases such as lichen planus, candidiasis, angular cheilitis, recurrent aphthous stomatitis, recurrent herpes labialis,
20 glossitis/stomatitis migrans, discoid lupus lesions, burning mouth syndrome, burning mouth syndrome, mucositis a.o.

In another embodiment, it might be used as eye lubricant and as carrier of active substances to the eyes.

Further, it may be used as lubricant in massage and sexual activities.

- 25 In another embodiment, it might be used as a carrier of active substances to the vagina, urethra, uterus, nose, sinus, throat, ears, or rectum or any other mucosal or serosal tissue or skin.









Finally it might be useful in lubricating skin to skin friction, devices-skin friction, such as with prosthetic devices, and friction of device parts such as endoscope against sleeves and mouth-
30 guards and intra-device friction such as wires in an endoscope.












EXAMPLE 1











A number of aqueous gel compositions were prepared by adding the pre-weighted and premixed polymers to the water at low temperature (under 3°C) while agitating the water with an Electrolux Stick Mixer ESTM 6200 at highest speed. The agitation was maintained until no more dry particles or lumps could be seen.











The quality of the individual gel compositions appears from the below table I.

Table I

Material 1 (M1)	Material 2 (M2)	Molecular structure material 1	Molecular structure material 2	Quality of gel	Comment	Conc. (M1%,M2%)
Methocel K250M (HPMC)	Polyox 301			- + ++ +++ +++		0,03/0,3 0,1/0,3 0,3/0,3 0,8/0,3 1,0/0,3
Methocel K250M (HPMC)	-		-	+ ++ ++	No stringiness (all conc.)	0.6 0.8 1.0
Polyox 301	-		-	-	Water like with stringiness	0.3
Methocel K250M (HPMC)	Polyox N60K			++	Thin	0,8/1,5
Methocel K250M (HPMC)	Polyox N12K			++	Thin	0,8/0,75

Material 1 (M1)	Material 2 (M2)	Molecular structure material 1	Molecular structure material 2	Quality of gel	Comment	Conc. (M1%,M2%)
Maize starch	-			-	Jelly	10
Maize starch	Polyox 301			+	Jelly/gel	5/0,3
CMC 40.000	Polyox 301	 R = H or CH ₂ CO ₂ H		+++		0,8/0,3
Kelcogel (gellan gum)	Polyox 301			++ ++ -	Jelly	0,1/0,3 0,2/0,3 0,8/0,3
Methocel K15M (HPMC)	Polyox 301			++		0,8/0,3
Keltrol (xanthan gum)	Polyox 301			-	Jelly	0,7/0,3

Material 1 (M1)	Material 2 (M2)	Molecular structure material 1	Molecular structure material 2	Quality of gel	Comment	Conc. (M1%,M2%)
Methylcellulose SGA	-	 <p>R = H or CH₃</p>	-	- +	Very thin	2 5
Methylcellulose SGA	Polyox 301	 <p>R = H or CH₃</p>		+(+)		5/0,3
Methocel A40M (MC)	Polyox 301			+	A thin gel	0,8/0,3
Methocel fast hydrating K100M (HPMC)	Polyox 301			++		0,8/0,3
Methocel K4M (HPMC)	Polyox 301			+		0,8/0,3
Methocel K4M (HPMC)	-		-	-		0,8

Material 1 (M1)	Material 2 (M2)	Molecular structure material 1	Molecular structure material 2	Quality of gel	Comment	Conc. (M1%,M2%)
Methocel F4M (HPMC)	Polyox 301			-		0,8/0,3
Methocel F4M (HPMC)	-		-	-		0,8
Methocel E4M (HPMC)	Polyox 301			+		0,8/0,3
Methocel E4M (HPMC)	-		-	-		0,8
Methocel A4M (MC)	Polyox 301			+		0,8/0,3
Methocel A4M (MC)	-		-			0,8
Arabic gum	-			+(+)	-	
Arabic gum	Polyox 301			++	-	

EXAMPLE 2

An aqueous vehicle having the following composition:

- 5 0.2 % by weight of polyethylene oxide (Polyox WSR 301)
- 0.5 % by weight of HPMC (Methocel K250M)
- q.s. water

10 was prepared by adding the polyethylene oxide and HPMC to ice-cold water while agitating the mixture with an Electrolux Stick Mixer ESTM 6200 at highest speed. The agitation was maintained until no more dry particles or lumps could be seen. Sucralfate in an amount of 5.3 % by weight of the above vehicle was added under stirring to obtain a sucralfate-containing gel composition.

15 The sucralfate-containing gel composition was administered to patients with xerostomia also having inflammatory mucosal lesions twice daily at a dose of one spoonful per dose. Significant symptom relief was observed after a few days of treatment.

LIST OF REFERENCES

US 4,740,365

US 5,068,225

US 6,133,325

5 US 8,623,334

WO 92/03124

WO 92/09256

WO 02/087519

US 2005/0226822

10 US 2005/0244521

WO 2006/028578

WO 2006/124219

EP 0 613 684

CLAIMS

1. An aqueous gel composition comprising:

a. water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition; and

b. a local anaesthetic agent or an analgesic agent;

for use as a local anaesthetic or analgesic for mucosal membranes.

2. The aqueous gel composition according to claim 1, wherein the water content is at least 95 % by weight of the composition, more preferably at least 97 % by weight of the composition.

3. The aqueous gel composition according to claim 1 or 2, wherein the water content is above 98 % by weight of the composition, more preferably in the range 98.5-99.5 % by weight of the composition, such as in the range 98.7-99.3 % by weight of the composition.

4. The aqueous gel composition according to any one of the preceding claims, wherein the at least one polysaccharide is selected from the group consisting of cellulose and derivatives thereof, optionally substituted alkylcelluloses, gums, pectin, carrageenan and alginates.

5. The aqueous gel composition according to any one of the preceding claims, wherein the at least one cellulose and derivatives thereof, optionally substituted alkylcelluloses, gums, pectin and carrageenan is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, tara gum, guar gum, arabic (Acacia) gum, gellan gum, pullulan gum, cassia gum, carob gum, carreegeenan, pectin, locust bean gum, welan gum, konjac, and karaya, preferably selected from the group consisting of methylcellulose, carboxy-methylcellulose, hydroxypropyl methylcellulose, xanthan gum, and guar gum, more preferably methylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, gellan gum or xanthan gum.

6. The aqueous gel composition according to any one of the preceding claims, wherein the at least one cellulose and derivatives thereof is selected from methylcellulose and hydroxypropyl methylcellulose, and is preferably hydroxypropyl methylcellulose.

7. The aqueous gel composition according to any one of the preceding claims, wherein
5 the at least one high molecular weight polyethylene oxide is of a molecular weight of at least 200,000, preferably of a molecular weight of at least 600,000, more preferably of a molecular weight of at least 1,000,000, preferably of a molecular weight in the range 1,000,000 to 7,000,000, more preferably of a molecular weight in the range 1,000,000-6,000,000, such as
10 of a molecular weight in the range 1,000,000 to 5,000,000, such as of a molecular weight in the range 1,000,000 to 4,000,000.

8. The aqueous gel composition according to any one of the preceding claims, wherein the content of the at least one polysaccharide is in the range 0.1-3 % by weight of the composition, more preferably in the range 0.3-2.0 % by weight of the composition, such as
15 in the range 0.4-1.5 % by weight of the composition, more preferably in the range 0.5-1.5 % by weight of the composition, such as about 0.6-1.2 % by weight of the composition, such as about 0.8 % by weight of the composition.

9. The aqueous gel composition according to any one of the preceding claims, wherein the content of the at least one high molecular weight polyethylene oxide is in the range 0.05-
20 2 % by weight of the composition, more preferably in the range 0.1-1 % by weight of the composition, more preferably in the range 0.1-0.5 % by weight of the composition, such as about 0.3 % by weight of the composition.

10. The aqueous gel composition according to any one of the preceding claims, wherein the content of the at least one polysaccharide in the composition is in the range 0.5-1.5 % by weight of the composition, preferably in the range 0.6-1.2 % by weight of the composition,
25 such as about 0.8 % by weight of the composition, and the content of the at least one high molecular weight polyethylene oxide in the composition is in the range 0.1-1 % by weight of the composition, more preferably in the range 0.1-0.5 % by weight of the composition, such as about 0.3 % by weight of the composition.

11. The aqueous gel composition according to any one of the preceding claims, wherein
30 the local anaesthetic agent or analgesic agent are selected from procaine, amethocaine, cocaine, lidocaine (also known as Lignocaine), prilocaine, bupivacaine, levobupivacaine, ropivacaine, mepivacaine, dibucaine, benzocaine, tetracaine, etidocine, and ropivacaine.

12. The aqueous gel composition according to any one of the preceding claims, further comprising at least one additive selected from the group consisting of a flavouring agent, a taste correcting substance, a colourant, a pH regulating agent, a preservative, a texture modifier, a therapeutically active agent, such as a caries-preventive agent, an antifungal agent, an antibacterial agent, an antiviral agent, and an anti-parasitic agent.

13. The aqueous gel composition according to any one of claims 1-12 for use as an oral or endoscopic local anaesthetic or analgesic.

14. An aqueous gel composition comprising:

- 10 a. water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition; and
- 15 b. optionally a caries-preventive agent, an antifungal agent, an antibacterial agent, an antiviral agent, an anti-parasitic agent, a flavouring agent, a taste correcting substance, a texture modifier, a colourant, a pH regulating agent, and a preservative;

for use as a saliva substitute.

15. A use of an aqueous gel composition comprising:

- 20 a. water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90 % by weight of the composition; and
- b. optionally a caries-preventive agent, an antifungal agent, an antibacterial agent, an antiviral agent, an anti-parasitic agent, a flavouring agent, a taste correcting substance, a texture modifier, a colourant, a pH regulating agent, and a preservative;

25 for use as a food lubricant.

16. An aqueous gel composition comprising water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is above 98 % by

weight of the composition, more preferably in the range 98.5-99.5 % by weight of the composition, such as in the range 98.7-99.3 % by weight of the composition.

17. The composition according to any one of claims 14-16, wherein the at least one polysaccharide is as defined in any one of claims 4-6.

5

18. The composition according to any one of claims 14-17, wherein the at least one high molecular weight polyethylene oxide is as defined in claim 7.

19. The composition according to any one of claims 14-18, wherein the content of the at least one polysaccharide in the composition is in the range 0.5-1.5 % by weight of the composition, preferably in the range 0.6-1.2 % by weight of the composition, such as about 0.8 % by weight of the composition, and the content of the at least one high molecular weight polyethylene oxide in the composition is in the range 0.1-1 % by weight of the composition, preferably in the range 0.1-0.5 % by weight of the composition, such as about 0.3 % by weight of the composition.

15 20. The composition according to any one of claims 14-19, further comprising at least one additive selected from the group consisting of a therapeutically active agent, such as a local anaesthetic agent, an analgesic agent, an anti-infective agent such as an antifungal agent, an antibacterial agent, an antiviral agent, and an anti-parasitic agent, a caries-preventive agent, a flavouring agent, a taste correcting substance, a texture modifier, a colourant, a pH
20 regulating agent, and a preservative.

21. An aqueous gel composition according to claims 16-20 for use as a lubricant for mucosal membranes, serosal surfaces and skin and for submucosal applications.

25 22. An aqueous gel composition according to claims 16-20 for use as a lubricant for devices and appliances.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2015/061282

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K47/10 A61K9/06 A61K47/36 A61K47/38 A61K8/73
 A61K8/86
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 068 225 A (PENNEL PHILLIP E [US] ET AL) 26 November 1991 (1991-11-26)	14
Y	column 4, lines 29-53; table 3 column 5, lines 1-34	1-22
X	US 6 133 325 A (SCHWARTZ HERBERT E [US] ET AL) 17 October 2000 (2000-10-17)	14,16-22
	column 5, lines 31-55 column 6, line 66 - column 7, line 23 column 8, lines 52-63; examples	
X	WO 92/09256 A1 (MEDICAL POLYMERS INC [US]; GOLD MARVIN H [US]) 11 June 1992 (1992-06-11)	14
Y	page 3, line 22 - page 4, line 16 page 2, lines 9-18	1-22
	----- -/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 3 July 2015	Date of mailing of the international search report 10/07/2015
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Giménez Miralles, J
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2015/061282

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/087519 A2 (GILLETTE CO [US]; DODD KENNETH T [US]; LAWLER JOHN V [US]; COUGHLIN CH) 7 November 2002 (2002-11-07)	14
Y	page 10, lines 16-25; examples 10-14 -----	1-22
Y	US 8 623 334 B1 (WICKENHAUSER ALAN J [US] ET AL) 7 January 2014 (2014-01-07) example 8 -----	1-22
Y	US 2005/226822 A1 (GARBERS CHRISTINE [DE] ET AL) 13 October 2005 (2005-10-13) paragraphs [0006], [0042]; examples -----	1-22
Y	EP 0 613 684 A1 (BLOCK DRUG CO [US]) 7 September 1994 (1994-09-07) page 3, lines 11-18; examples 2,4 -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2015/061282

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5068225	A	26-11-1991	NONE
US 6133325	A	17-10-2000	AT 376567 T 15-11-2007 AU 754787 B2 28-11-2002 AU 7698598 A 04-01-1999 CA 2294200 A1 23-12-1998 DE 69838614 T2 28-08-2008 EP 1002002 A1 24-05-2000 JP 4986311 B2 25-07-2012 JP 2002511897 A 16-04-2002 US 5906997 A 25-05-1999 US 6017301 A 25-01-2000 US 6034140 A 07-03-2000 US 6133325 A 17-10-2000 WO 9858011 A1 23-12-1998
WO 9209256	A1	11-06-1992	NONE
WO 02087519	A2	07-11-2002	AU 2002256322 A1 11-11-2002 BR 0209274 A 15-06-2004 CA 2445283 A1 07-11-2002 EP 1435896 A2 14-07-2004 MX PA03009923 A 29-01-2004 US 2003053980 A1 20-03-2003 WO 02087519 A2 07-11-2002
US 8623334	B1	07-01-2014	US 8623334 B1 07-01-2014 US 8968710 B1 03-03-2015
US 2005226822	A1	13-10-2005	AU 2003218853 A1 10-11-2003 CA 2483000 A1 06-11-2003 CA 2711709 A1 06-11-2003 EP 1496851 A1 19-01-2005 EP 2319489 A2 11-05-2011 HR P20041100 A2 31-12-2004 IL 164694 A 31-10-2012 IL 206752 A 31-12-2012 JP 4307269 B2 05-08-2009 JP 2005529125 A 29-09-2005 US 2005226822 A1 13-10-2005 WO 03090703 A1 06-11-2003
EP 0613684	A1	07-09-1994	AT 183638 T 15-09-1999 AU 670481 B2 18-07-1996 BR 9400544 A 18-10-1994 CA 2116799 A1 03-09-1994 DE 69420161 D1 30-09-1999 DE 69420161 T2 06-04-2000 DK 0613684 T3 20-03-2000 EP 0613684 A1 07-09-1994 ES 2136161 T3 16-11-1999 GR 3031560 T3 31-01-2000 JP 2794388 B2 03-09-1998 JP H07101856 A 18-04-1995 US 5496558 A 05-03-1996